Since 2022
Partners
Pipeline
We select targets with clear opportunity for a precision medicine strategy to address three target categories in what we consider “therapeutic white spaces” of underserved populations.
Validated oncogene targets
Undruggable targets
Novel cancer targets
Pipeline
Target
Discovery
Phase 1
Phase 2
Phase 3
STX-478
Mut-Sel H1047 PI3Kα
STX-EGFR-EXON20
Mut-Sel EGFR Exon 20 insertion
Other
Best-in-class Discovery Programs Against Validated Oncogene Targets
First-in-Class Discovery Programs Against Undruggable Targets
First-in-Class Discovery Programs Against Novel Cancer Targets
Partners
Since 2022
Press Releases
For Inquiries
Address
1 Winthrop Square,
Suite 400
Boston, Ma 02110
Phone
(718) 288-5760